Search

Sustained Release Inner Ear Delivery of Corticosteroid

Company: O-RAY PHARMA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: … or total deafness. Many patients with severe hearing loss, a far larger group, are not currently implanted for fear of losing their residual hearing. Steroids have been shown to have a protective effect against hearing loss caused bycochlear trauma. O-Ray's drug… more

Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: … by children over tablets and capsules, are often poorly palatable and thus suffer from poor compliance. Ad-hoc formulations can also alter the performance and risk the likelihood of under or over-dosing. Orbis Biosciences's has developed a free-flowing drug-loaded… more

Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease

Company: CALASIA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: DESCRIPTION (provided by applicant): Mosquito-borne members of the Flavivirus family include four serotypes of dengue virus (DENV1-4) and West Nile Virus (WNV) and are classified as re-emerging pathogens due to the frequency and severity of recent epidemics. There are an estimated 100 million DENV… more

Ion Channel Screening Using Photoswitches

Company: PHOTOSWITCH BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: … that allow the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug… more

Ion Channel Screening Using Photoswitches

Company: PHOTOSWITCH BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: … the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug discovery… more

High Throughput Data Collection Software for Multiplexed TEM Samples

Company: NANOIMAGING SERVICES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: DESCRIPTION (provided by applicant): Transmission electron microscopy is a valuable technique for characterizing biological therapeutics, vaccines, drug delivery vehicles, and nanoparticles. There is considerable evidence that links the physical propertiesof these samples to… more

Peripheral administration of nonpeptide somatostatin agonists for ophthalmic dise

Company: CRINETICS PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: Project Summary With an increasing older population, including the generational aging of the baby boomers , age-related eye diseases are common and becoming more prevalent. Currently, it is estimated that 11 million Americans suffer from age-related macular degeneration (AMD) - a number that is… more

Development of Technologies that Address the Complex Architecture of the Face During the Treatment of Severe Facial Burn Injury

Company: KeraNetics, LLC Agency/Program/Year/Phase: DOD / SBIR / 2014 / 1
Abstract: …ovative 3D printed halofuginone eluding keratin-based wound dressing that could potentially improve healing rates and reduce scarring and contracture in our burned Wounded Warriors. The proposed dressing will be formulated and tested for mechanical properties and drug delivery… more

Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive

Company: SENTIEN BIOTECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: DESCRIPTION (provided by applicant): The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product (the Sentinel ) in a first-in-man study to assess safety and preliminary efficacy. Fifteen post-cardiac surgery patients that are diagnosed with acute kidney injury and… more

High Specific Activity Sn-117m by Post Irradiation Isotope Separation

Company: IsoTherapeutics Group LLC Agency/Program/Year/Phase: DOE / SBIR / 2014 / 1
Abstract: … of interest in a variety of biomedical applications, including several in the fields of oncology and cardiology. While tin-117m can be produced through a variety of methods, there are limiting factors that must be addressed in order to facilitate drug… more

Development of an iPSC-derived human vascular system for drug discovery and devel

Company: HEMOSHEAR, LLC Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated into vascular endothelial (iEC) and smooth muscle (iSMC)cells and hold immense… more

Development of an iPSC-derived human hepatocyte platform for drug development.

Company: HEMOSHEAR, LLC Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: … terminally differentiated into hepatocytes, which potentially makes them an attractive, cost-effective resource compared to primary human hepatocytes. Moreover, the ability to standardize a platform to a single human donor, or donor(s) who may include known genetic drug… more

Innovative Device to Improve Safety of Preparing and Administering Chemotherapy

Company: J AND J SOLUTIONS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: ? DESCRIPTION (provided by applicant): Manual drug compounding of chemotherapy medications permits deadly dosing errors and toxic drug exposure and therefore poses unnecessary risks to patients and healthcare professionals. Some robotic compounding devices have been… more

HERMES-Based X-Ray Strip Detector

Company: Sydor Instruments, LLC Agency/Program/Year/Phase: DOE / SBIR / 2014 / 2
Abstract: … as compared to present techniques. By acquiring data simultaneously at many points, the quality and quantity of data will be improved 100-fold from the current state of the art. These detectors will benefit a wide range of applications ranging from structure-based drug… more

Porphyrin-DNA Origami Constructs as Bioscavengers for Organophosphates

Company: Parabon NanoLabs, Inc. Agency/Program/Year/Phase: DOD / SBIR / 2014 / 1
Abstract: The recent use of organophosphate (OP) nerve agents against combatants and civilians in Syria has validated the importance of developing new drugs and biologics that sequester and catalytically degrade organophosphate (OP) nerve agents in the body before they cause morbidity and… more

SBIR Phase I: A Novel Method for Identifying Synthetic Binding Agents for Targeting Drugs to Specific Tissues

Company: Parabon NanoLabs, Inc. Agency/Program/Year/Phase: NSF / SBIR / 2014 / 1
Abstract: The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is the development of a screening method to reliably identify binding agents that can be used to target drugs to specific tissues or cell types. Targeting drugs… more

Computational platform for Green Chemistry

Company: LEADSCOPE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: DESCRIPTION (provided by applicant): The field of green chemistry was established in order to reduce or even eliminate any negative impact from the introduction of new chemical products such as new pesticides, cosmetics, or drugs to human health or the environment. Unfortunately… more

Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ

Company: ABEOME CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: …mprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging drug… more

Glucagon Mini-Dosing Pen for Treatment of Hypoglycemia

Company: XERIS PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: DESCRIPTION (provided by applicant): The program outlined in this application has been designed to accelerate the development and commercialization of a Glucagon Mini-Dose Pen to change the paradigm for treatment of moderate hypoglycemia in insulin-using diabetics. This research is directly relevant… more

SBIR Phase I: A Learning Drug Discovery Platform in the Cloud

Company: Acelot, Inc. Agency/Program/Year/Phase: NSF / SBIR / 2014 / 1
Abstract: This Small Business Innovation Research (SBIR) Phase I project proposes to develop a web-based learning software platform for collaborative drug discovery and optimization. Current drug discovery software tools do not support the sophisticated data management… more

Remote-Access Data Enclave for HRS/PSID Analysis

Company: ACUMEN, LLC Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: …, health, retirement and social circumstances of the American public. MedRIC has created comprehensive CMS-linked research files for these surveys that include all forms of information from Medicare and Medicaid claims for institutional, physician, and pharmaceutical services.… more

A Practical Tool for Managing the Complexity of Biologics Process Manufacturing

Company: ADVANCED PROCESS COMBINATORICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 2
Abstract: DESCRIPTION (provided by applicant): Biologics manufacturing based on cell culture techniques represents a tremendous advance in the pharmaceutical industry. The use of biological rather than chemical processes result in unique therapeutics with greater profitability, a… more

Confocal and Autofluorescence Imaging of Macular Degeneration using a Low Cost Di

Company: AEON IMAGING, LLC Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: … countries. The specialized imaging techniques provide far better detection of key lesions, compared to color fundus photography, and even this basic technology is not available for all patients. New treatments do save sight, using portable lasers and injectable drugs, but… more

Development of selective Cav3 channel blockers for treatment of neuropathic pain

Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / SBIR / 2014 / 1
Abstract: ….2) in the DRG neurons of rats. Conversely, gene knockout, antisense knockdown, or silencing of the Cav3.2 isoform produces good apparent pain relief in both neuropathic and inflammatory pain in rats or mice. In short, the T-type Ca2 channels appear to be excellent drug targets… more

Fast-Timing Large-Area Detector for Neutron Scattering

Company: Radiation Monitoring Devices, Inc Agency/Program/Year/Phase: DOE / SBIR / 2014 / 1
Abstract: … to homeland security, nuclear and high-energy physics research, and the development of new sources to effectively address our nations future energy needs. The proposed detectors will also result in scientific research leading to the development of new drugs,… more